摘要
目的 评价并比较新型免疫抑制剂普乐可复 (FK5 0 6 )对预防同种肾移植受者排斥反应的疗效及安全性。方法 随机将 98例肾移植受者分成 2组。(1)FK5 0 6组 (n =40 ) :主要用药为FK5 0 6 +霉酚酸酯 (MMF) +泼尼松 (Pred) ;(2 )环孢素A(CsA组 ) (n =5 8) :主要用药为 :CsA +MMF +Pred。结果 2组受者平均随访时间为 12 .5个月。FK5 0 6组有 2例 (5 .0 % )、CsA组有 9例(15 .5 % )出现经病理证实的急性移植肾排斥反应 ;FK5 0 6组肾移植 1年人 /肾存活率为 10 0 % /10 0 % ,CsA组为 10 0 % / 94.8% ;FK5 0 6组皮质激素用量低于CsA组 ,并有 12例受者已停用Pred ;FK5 0 6组发生高血糖较多见 ,共 7例 ,CsA组以多毛、齿龈增生、肝功能异常较多见 ;FK5 0 6组有 9例 (2 2 .5 % )、CsA组有 11例 (18.9% )发生感染。结论 新型免疫抑制剂FK5 0 6与MMF联合应用使急性移植肾排斥反应率降低 ,皮质激素用量减少。调整好应用剂量有助于减少药物的不良反应及预防排斥反应发生。
Objective To compare the efficacy and safety of Tacrolimus (FK506) and Neoral CsA in conjunction with MMF (2.0 g/d) and steroid in preventing renal allograft rejection.Methods 98 cases of renal transplant recipients were randomly divided into two groups: FK506 group ( n =40), receiving tacrollimus, MMF and prednison (Pred); CsA group ( n =58), receiving CsA, MMF and Pred.Results The mean follow up time in both two groups was 12.5 months. Acute transplanted renal rejection occurred in 2 cases in FK506 group and 9 cases in CsA group respectively. The one year person/kidney survival rate was 100%/100% in FK506 group and 100%/94.8% in CsA group respectively. The dosage of Pred in FK506 group was lower than in CsA group. 12 cases in FK506 group had stopped using Pred. Hypergly cermia occurred in 7 cases in FK 506 group. Polytricosis, gingival hyperplasia and liver function disorder dominantly occurred in CsA group. Infection was found in 9 cases of FK506 group and 11 cases of CsA group respectively.Conclusion FK506 combined with MMF could decrease the occurrence of acute transplanted renal rejection and the dosage of Pred. The good adjustment of the dose of FK506 is helpful for reducing the side effects and preventing rejection.
出处
《中华器官移植杂志》
CAS
CSCD
2000年第2期117-118,共2页
Chinese Journal of Organ Transplantation
关键词
普乐可复
肾移植
排斥反应
预防
FK506
Renal transplantation
Grafting rejection
